Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BARDA Signs Biodefense Contracts With GSK And Soligenix

This article was originally published in The Pink Sheet Daily

Executive Summary

Under a pair of agreements announced Sept. 19, the HHS unit will stockpile 60,000 doses of GSK’s inhalation anthrax treatment and will fund development of a treatment for GI acute radiation syndrome by New Jersey biotech Soligenix.

You may also be interested in...



CROs Getting Govt. Support To Help Countermeasure Sponsors

BARDA’s Clinical Studies Network aims to reduce the number of countermeasure development failures.

HGSI Gets Slightly Increased Buyout Bid, Accepts GSK Offer Of $3.6 Billion

After three months of battling, with lupus drug Benlysta still struggling, Human Genome Sciences accepted a modestly increased sales offer from partner GlaxoSmithKline.

Deals Of The Week: GlaxoSmithKline/BARDA, Evotec/Roche, F-Star/Merck Serono

Each week, “The Pink Sheet” presents commentary on some of the week’s most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at http://invivoblog.blogspot.com.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM007836

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel